Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis.
Arecco L, Blondeaux E, Bruzzone M, Latocca MM, Mariamidze E, Begijanashvili S, Sokolovic E, Gentile G, Scavone G, Ottonello S, Boutros A, Vaz-Luis I, Saura C, Anderson RA, Demeestere I, Azim HA Jr, de Azambuja E, Peccatori FA, Del Mastro L, Partridge AH, Lambertini M. Arecco L, et al. Among authors: bruzzone m. ESMO Open. 2023 Dec;8(6):102031. doi: 10.1016/j.esmoop.2023.102031. Epub 2023 Oct 23. ESMO Open. 2023. PMID: 37879234 Free PMC article.
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A, Tanda ET, Croce E, Catalano F, Ceppi M, Bruzzone M, Cecchi F, Arecco L, Fraguglia M, Pronzato P, Genova C, Del Mastro L, Lambertini M, Spagnolo F. Boutros A, et al. Among authors: bruzzone m. Eur J Cancer. 2023 Jul;188:64-79. doi: 10.1016/j.ejca.2023.04.010. Epub 2023 Apr 24. Eur J Cancer. 2023. PMID: 37196485 Free article. Review.
Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.
Molinelli C, Jacobs F, Agostinetto E, Nader-Marta G, Ceppi M, Bruzzone M, Blondeaux E, Schettini F, Prat A, Viale G, Del Mastro L, Lambertini M, de Azambuja E. Molinelli C, et al. Among authors: bruzzone m. ESMO Open. 2023 Aug;8(4):101592. doi: 10.1016/j.esmoop.2023.101592. Epub 2023 Jul 4. ESMO Open. 2023. PMID: 37413762 Free PMC article.
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.
Debien V, Agostinetto E, Bruzzone M, Ceppi M, Martins-Branco D, Molinelli C, Jacobs F, Nader-Marta G, Lambertini M, de Azambuja E. Debien V, et al. Among authors: bruzzone m. Clin Breast Cancer. 2024 Jul;24(5):421-430.e3. doi: 10.1016/j.clbc.2024.02.012. Epub 2024 Feb 21. Clin Breast Cancer. 2024. PMID: 38514306 Clinical Trial.
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.
Blondeaux E, Xie W, Carmisciano L, Mura S, Sanna V, De Laurentiis M, Caputo R, Turletti A, Durando A, De Placido S, De Angelis C, Bisagni G, Gasparini E, Rimanti A, Puglisi F, Mansutti M, Landucci E, Fabi A, Arecco L, Perachino M, Bruzzone M, Boni L, Lambertini M, Del Mastro L, Regan MM. Blondeaux E, et al. Among authors: bruzzone m. EClinicalMedicine. 2024 Mar 20;70:102501. doi: 10.1016/j.eclinm.2024.102501. eCollection 2024 Apr. EClinicalMedicine. 2024. PMID: 38685923 Free PMC article.
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, Bernstein Molho R, Linn SC, Pogoda K, Carrasco E, Punie K, Agostinetto E, Lopetegui-Lia N, Phillips KA, Toss A, Rousset-Jablonski C, Acheritogaray M, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Vasconcelos de Matos L, Mariño M, Teixeira L, Graffeo R, Rognone A, Chirco A, Antone N, Abdou Y, Marhold M, Božović-Spasojević I, Cortés Salgado A, Carmisciano L, Bruzzone M, Curigliano G, Prat A, Lambertini M. Schettini F, et al. Among authors: bruzzone m. Cancer. 2024 Aug 15;130(16):2746-2762. doi: 10.1002/cncr.35323. Epub 2024 May 16. Cancer. 2024. PMID: 38752572 Free article.
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study.
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L. Molinelli C, et al. Among authors: bruzzone m. Eur J Cancer. 2024 Nov 4;213:115113. doi: 10.1016/j.ejca.2024.115113. Online ahead of print. Eur J Cancer. 2024. PMID: 39536433 Free article.
Simultaneous detection of membrane contact dynamics and associated Ca2+ signals by reversible chemogenetic reporters.
García Casas P, Rossini M, Påvénius L, Saeed M, Arnst N, Sonda S, Fernandes T, D'Arsiè I, Bruzzone M, Berno V, Raimondi A, Sassano ML, Naia L, Barbieri E, Sigismund S, Agostinis P, Sturlese M, Niemeyer BA, Brismar H, Ankarcrona M, Gautier A, Pizzo P, Filadi R. García Casas P, et al. Among authors: bruzzone m. Nat Commun. 2024 Nov 12;15(1):9775. doi: 10.1038/s41467-024-52985-0. Nat Commun. 2024. PMID: 39532847 Free PMC article.
456 results